Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living
Go back to Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 146.23 -5.6 (3.69%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $151.83 | 52 Week High | $58.46 | |||
| Open | $152.63 | 52 Week Low | $31.25 | |||
| Day High | $152.63 | P/E | N/A | |||
| Day Low | $146.06 | EPS | $-0.69 | |||
| Volume | 2,816,257 | |||||
